Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Seres Theraptc (NQ: MCRB )

20.50 USD -0.20 (-0.97%)
Streaming Delayed Price Updated: 1:52 PM EDT, Apr 23, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 194,685
Open 20.22
Bid (Size) 20.50 (2)
Ask (Size) 20.57 (1)
Prev. Close 20.70
Today's Range 20.00 - 20.89
52wk Range 3.410 - 38.50
Shares Outstanding 91,549,412
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer
Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental... 
From PR Newswire
Seres Therapeutics to Present at Jefferies Microbiome-Based Therapeutics Summit
Seres Therapeutics, Inc. (Nasdaq: MCRB) a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will present at the... 
From Business Wire News Releases

Performance

YTD
-18.20%
-18.20%
1 Month
+0.20%
+0.20%
3 Month
-15.18%
-15.18%
6 Month
-27.94%
-27.94%
1 Year
+448.13%
+448.13%

More News

Read More
Tessera Therapeutics Strengthens Leadership Team to Advance ‘Gene Writing’ Platform & Accelerate Therapeutic Development
From Business Wire News Releases
Seres Therapeutics to Present at the 31st Annual Oppenheimer Healthcare Conference
From Business Wire News Releases
Seres Therapeutics Announces Discontinuation of Enrollment in SER-401 Study in Metastatic Melanoma
From Business Wire News Releases
Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target
From PR Newswire
Add Up The Parts: LABU Could Be Worth $119
Tags ETFs
From ETF Channel
Seres Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Updates
From Business Wire News Releases
Seres Therapeutics Announces Achievement of Target Enrollment in SER-287 Phase 2b ECO-RESET Study for Ulcerative Colitis
From Business Wire News Releases
MCRB Crosses Below Key Moving Average Level
Tags Stocks
From Market News Video
Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.